Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in Peripheral Artery Disease
NCT06534944Phase 2Completed
- Sponsor
- University of Oklahoma
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide riboside in peripheral artery disease (PAD), sponsored by University of Oklahoma. Started Feb 2023; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT06534944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534944.